Strive Health Emphasizes Redefining Kidney Care and Value-Based Models

According to a recent LinkedIn post from Strive Health, the company is using National Kidney Month to emphasize the need to “redefine” kidney care for an estimated 37 million affected individuals in the U.S. The post points readers to expert content, including a webcast on future kidney care models and an article on the impact of SGLT2 therapies on kidney health.

The company’s LinkedIn post highlights a focus on education, multidisciplinary partnerships, and patient-centric care models that meet patients “where they are.” This emphasis suggests Strive Health is positioning itself within value-based care and emerging drug paradigms, potentially reinforcing its relevance to payers, providers, and partners seeking improved outcomes and cost containment in chronic kidney disease.

The references to nephrologists, cardiologists, primary care physicians, and other care team members indicate a strategy built on integrated care and collaboration with clinical stakeholders. For investors, this may imply that Strive Health is trying to deepen its provider relationships and embed its services more firmly into clinical workflows, which could support long-term contract stability and expand its addressable market.

By spotlighting SGLT2 innovation and “expert perspectives on 2026,” the post suggests that the company is aligning its care model with evolving clinical standards and upcoming practice trends. This alignment could enhance Strive Health’s differentiation versus traditional dialysis-centered approaches and may help capture value from earlier-stage intervention in kidney disease, which is increasingly attractive to value-based payers.